Belantamab mafodotin-blmf is now indicated for adult patients with relapsed or refractory myeloma who have received at least 4 prior therapies.
Ryan Nolan, PharmD Candidate 2021
Advertisement
Articles by Ryan Nolan, PharmD Candidate 2021
On October 22, 2020, the FDA approved remdesivir (Veklury; Gilead) as the first treatment for coronavirus disease 2019 (COVID-19).
Advertisement
Latest Updated Articles
Belantamab mafodotin-blmf for Relapsed or Refractory Multiple MyelomaFebruary 12th 2021
Remdesivir in the Treatment of COVID-19January 14th 2021
Advertisement
Advertisement
Trending on Drug Topics
1
ACIP's Vacancy Leaves Pharmacists Navigating COVID-19 Confusion
2
COVID-19 in 2026: Why the Virus Still Threatens Vulnerable Patients
3
FDA-Approved Sunscreen Filter Bemotrizinol Debuts in New US Products
4
The Drug Price Paradox: PBMs, Pharmacies, and the Path to Affordability
5